Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

A compound and fusion technology, which can be applied in drug combination, medical preparations containing active ingredients, organic chemistry, etc., can solve the problem of wide therapeutic range of melatonin

Inactive Publication Date: 2005-02-16
NEURIM PHARMA
View PDF19 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] Clearly, there is a wide range of treatments utilizing melatonin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
  • Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
  • Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] N-(2,4-Dinitrophenyl)tryptamine (ML-25)

[0052]

[0053] 1mmol of tryptamine was dissolved in 100ml of water, and the pH value was adjusted to 8.3 with 2.5M sodium bicarbonate (NaHCO3), and 1.5% of 2,4-dinitrofluorobenzene solution dissolved in 200L of ethanol was added, and stirred at room temperature for 2 Hour. After precipitation of the desired product, it is washed and dried. The product was obtained in 90% yield, the product which was well cleaved from the starting material showed a yellow spot (Rf=0.84) on TLC (chloroform, silica gel plate) under the same conditions.

Embodiment 2

[0055] N-(2,4-Dinitrophenyl)-5-methyltryptamine (ML-28)

[0056]

[0057] 1mmol of 5-methyltryptamine was dissolved in 100ml of water, and the pH value was adjusted to 8.3 with 2.5M sodium bicarbonate (NaHCO3), and 1.5% of 2,4-dinitrofluorobenzene solution dissolved in 200ml of ethanol was added. Stir at room temperature for 2 hours. After precipitation of the desired product, it is washed and dried. The product obtained was obtained in a yield of 85%, which showed a yellow spot (Rf=0.8) on TLC (chloroform, silica gel plate) under the same conditions.

Embodiment 3

[0059] 2,4-Dinitro-5-tryptophanylamino N-acetanilide (ML-26)

[0060]

[0061] Dissolve 1mmol tryptamine in 100ml water, adjust the pH value to 8.3 with 2.5M sodium bicarbonate (NaHCO3), add 1.5% 2,4-dinitro-5-fluoro-N-acetanilide solution dissolved in 200ml ethanol , stirred at room temperature for 2 hours. After precipitation of the desired product, it is washed and dried. The product was obtained in 80% yield, and under the same conditions, the product which was well cleaved from the starting material showed a yellow spot (Rf=0.76) on TLC (chloroform, silica gel plate).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence.

Description

field of invention [0001] The present invention relates to novel compounds, which are derivatives and analogs of tryptamine, pharmaceutical compositions containing them, and the use of these compounds in the preparation of pharmaceutical compositions for the treatment of various diseases. Background of the invention [0002] Melatonin is an important hormone secreted by the pineal gland of all vertebrates. In all mammals studied so far, including humans, melatonin production by the pineal gland shows signs of increasing at night, when light significantly suppresses melatonin production in the body. Melatonin is associated with dependence on photoperiods and coordination of physiological processes. The ability of an animal or human to respond to a melatonin signal depends on the melatonin receptor. Melatonin acts on the central nervous system (CNS) through receptors present in the brain to affect the function of the nervous system. Additionally, numerous studies have shown...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/404A61K31/4045A61P3/04A61P3/10A61P5/00A61P5/06A61P7/02A61P9/10A61P9/12A61P13/08A61P15/00A61P15/10A61P15/12A61P25/00A61P25/04A61P25/06A61P25/08A61P25/14A61P25/16A61P25/18A61P25/20A61P25/22A61P25/28A61P27/02A61P35/00A61P37/02A61P39/06C07D209/12C07D209/16
CPCC07D209/16C07D209/12A61P13/00A61P13/08A61P15/00A61P15/10A61P15/12A61P25/00A61P25/04A61P25/06A61P25/08A61P25/14A61P25/16A61P25/18A61P25/20A61P25/22A61P25/28A61P27/02A61P35/00A61P3/04A61P37/02A61P39/06A61P5/00A61P5/06A61P7/02A61P9/00A61P9/10A61P9/12A61P3/10
Inventor 纳瓦·奇撒贝尔姆士·劳丹
Owner NEURIM PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com